Parathyroid hormone (1-34) (human): Precision Tool for Calcium Homeostasis and Bone Metabolism Research

Executive Summary: Parathyroid hormone (1-34) (human) is a synthetic peptide fragment that serves as a highly potent parathyroid hormone 1 receptor agonist, facilitating precise modulation of calcium homeostasis in research settings (APExBIO). The peptide exhibits an IC50 of 0.22 nM for cAMP production in human kidney 293 cells, offering robust and reproducible signaling readouts (Huang et al., 2025). Its solubility profile (≥399.3 mg/mL in DMSO, ≥19.88 mg/mL in water) and high purity (>97.8%) enable reliable integration into diverse experimental workflows. In vivo studies demonstrate dose-dependent enhancements in trabecular and cortical bone mass, underpinning its utility in osteoporosis and bone metabolism research. The peptide's applications extend to advanced kidney organoid and assembloid models, where it provides a controlled means to interrogate PTH/PTHrP receptor signaling and calcium regulatory mechanisms.

Biological Rationale

Parathyroid hormone (1-34) (human) is a synthetic fragment containing the N-terminal 34 amino acids of the endogenous human parathyroid hormone (PTH), which is secreted by chief cells of the parathyroid glands (APExBIO). This fragment retains full biological activity with respect to PTH1R and PTH2R activation, making it the gold standard for probing calcium homeostasis and bone remodeling in vitro and in vivo (see related article). Unlike full-length PTH(1-84), the (1-34) fragment is more stable and provides consistent, receptor-selective pharmacology. The physiological relevance is anchored in its central role in regulating serum calcium and phosphate, primarily by acting on bone, kidney, and, indirectly, the intestine (Huang et al., 2025).

Mechanism of Action of Parathyroid hormone (1-34) (human)

PTH (1-34) peptide fragment binds with high affinity to the parathyroid hormone 1 receptor (PTH1R) and, to a lesser extent, the PTH2R, both of which are G protein-coupled receptors (Huang et al., 2025). Ligand binding induces conformational changes, activating intracellular Gs and Gq proteins. This triggers two primary signaling cascades:

• cAMP Pathway: Stimulation of adenylate cyclase increases cyclic AMP levels. In transfected human kidney 293 cells, PTH (1-34) elicits cAMP production with an IC50 of 0.22 nM under standard culture conditions (37°C, 5% CO₂, pH 7.4) (APExBIO).
• Inositol Phosphate Synthesis: Activation of phospholipase C via Gq increases intracellular inositol triphosphate (IP3), mobilizing calcium from endoplasmic reticulum stores (see related article).

Downstream effects include enhanced bone resorption (liberating calcium), increased renal tubular reabsorption of calcium and magnesium, and upregulation of 1α-hydroxylase in the kidney, which boosts production of active vitamin D (see related article). This, in turn, increases intestinal calcium absorption. The specificity and potency of PTH (1-34) make it ideal for dissecting these pathways in experimental systems.

Evidence & Benchmarks

• PTH (1-34) (human) stimulates cAMP production in human kidney 293 cells with an IC50 of 0.22 nM (37°C, serum-free conditions) (Huang et al., 2025, Table S2).
• Subcutaneous administration in male Fisher 344 rats (10 or 40 μg/kg/day) increases trabecular and cortical bone mass in a dose- and time-dependent manner over 28 days (APExBIO).
• The peptide is highly soluble: ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water (room temperature, neutral pH), but insoluble in ethanol (APExBIO).
• High purity (>97.8%, HPLC) and stability when stored as a desiccated solid at -20°C (APExBIO).
• In kidney assembloid models, precise modulation of PTH/PTHrP receptor signaling enables advanced study of nephron progenitor and collecting duct interactions (Huang et al., 2025, Figure 4).

This article updates prior reviews such as Parathyroid hormone (1-34) (human): Precision in Bone and... by integrating recent advances in kidney assembloid modeling and clarifying peptide solubility and storage constraints.

Applications, Limits & Misconceptions

PTH (1-34) (human) is primarily used for:

• Dissecting PTH/PTHrP receptor signaling in cell-based assays and organoid models
• Modeling osteoporosis and bone metabolism in rodents and tissue-engineered systems
• Analyzing calcium homeostasis and cAMP pathway activation in kidney research (see related article)
• Validating disease models in spatially patterned kidney assembloids, particularly via modulation of nephron-collecting duct crosstalk (Huang et al., 2025)

Common Pitfalls or Misconceptions

• Not a Diagnostic Reagent: PTH (1-34) (human) is for research use only and is not validated for therapeutic or clinical diagnostics (APExBIO).
• Storage Sensitivity: Long-term storage of peptide solutions (especially at room temperature or above 4°C) leads to rapid degradation and loss of activity.
• Solubility Constraints: The peptide is insoluble in ethanol; use only DMSO or water for stock preparation.
• Receptor Specificity: Effects are mediated primarily via PTH1R; off-target effects in non-expressing systems are minimal, but caution is warranted in interpreting indirect effects.
• In Vivo Model Dependency: Results from rodent models may not directly extrapolate to human clinical outcomes due to species differences in receptor expression and bone turnover rates.

This article clarifies boundaries relative to Unraveling Advanced R... by explicitly delineating where PTH (1-34) (human) should not be used and highlighting solubility/storage caveats.

Workflow Integration & Parameters

For optimal experimental reproducibility, PTH (1-34) (human) should be dissolved in DMSO or water at concentrations up to 399.3 mg/mL or 19.88 mg/mL, respectively. Prepare fresh aliquots and store desiccated at -20°C. Avoid repeated freeze-thaw cycles. In cell-based assays, start with 0.1–10 nM concentrations; titrate as needed for response curves. For in vivo rodent studies, subcutaneous dosing of 10–40 μg/kg/day is supported by peer-reviewed benchmarks (APExBIO).

In complex 3D kidney assembloid models, PTH (1-34) provides a means to selectively activate PTH1R/PTH2R signaling and evaluate downstream effects such as cAMP accumulation, inositol phosphate synthesis, and nephron maturation (Huang et al., 2025). For further optimization tips, see Scenario-Driven Best Practices with Parathyroid hormone..., which this article extends by incorporating recent advancements in assembloid and organoid workflow integration.

Conclusion & Outlook

Parathyroid hormone (1-34) (human) from APExBIO (SKU A1129) is a validated, high-purity reagent for dissecting PTH/PTHrP receptor signaling in advanced bone and kidney research. Its reproducibility, robust signaling, and compatibility with modern model systems—including spatially patterned kidney assembloids—make it an indispensable tool for elucidating the molecular architecture of calcium homeostasis. As organoid and assembloid platforms mature, precise PTH1R modulation will remain a cornerstone for mechanistic studies and disease modeling (Huang et al., 2025).